ASH 2020: Momelotinib treated patients with low plate counts with medium/high risk bone marrow fibrosis, who had positive results

Primary bone marrow fibrosis refers to bone marrow fibrosis, which is naturally formed due to certain genetic mutations.
most commonly between the ages of 50 and 70, with male patients accounting for the majority.
about half of primary bone marrow fibrosis patients have a mutation in the Janus Kinase 2 (JAK2) gene.
gene regulates certain enzymes involved in cell growth and immune response.
bone marrow fibrosis can be asymptomatic for many years.
in some patients, bone marrow fibrosis rapidly leads to anemia, decreased plate plate levels in the blood (plate plate reduction) or leukemia.
, exacerbation of anemia leads to weakness, fatigue, and weight loss.
biopharmaceutical company Sierra Oncology today reported the latest efficacy analysis of JAK-subject inhibitor Memelotinib in patients with combined plate small plate reduction bone marrow fibrosis.
data were presented at the 2020 annual meeting of the American Society of Hematology (ASH) by Dr Jean-Jacques Kiladjian, Director of the Clinical Research Center at St. Louis Hospital in Paris, France.
Kiladjian said: "A retrospective analysis of the Phase III SIMPLIFY study showed that the safety and efficacy of Momelotinib did not appear to be affected by baseline plateplate counts, compared to a decrease in the effectiveness of ruxolitinib therapy in patients with lower baseline plateboard counts.
addition to previous findings, these updated data analyses demonstrate that Momelotinib's treatment can be initiated and maintained regardless of baseline plateplate count."
。